Yaral Pharma’s Diclofenac epolamine topical system 1.3% is a nonsteroidal anti-inflammatory (NSAID) patch that requires a prescription and is used to treat small contusions, sprains, and strains that cause acute discomfort. Serving as the authorized generic of IBSA Pharma’s Flector®, this product is the most recent in Yaral’s line of therapeutic pain and endocrinology products. The brand has future plans to expand into the rheumatology, fertility, dermatology, and ophthalmology categories.
"We are excited to kick off the new year by launching the first of several products in our portfolio which includes authorized and complex generic medications," said Stephen Beckman, CEO, Yaral Pharma. "Like Flector, Yaral Pharma’s diclofenac epolamine topical system 1.3% offers patients a non-opioid topical treatment backed by more than 30 years of clinical experience. We are pleased to offer patients an accessible and affordable product that offers targeted topical pain relief and look forward to expanding our product line across a range of therapeutic areas in the months ahead."
Topical Pain Patches
Yaral Pharma Launches the 'Diclofenac Epolamine Topical System 1.3%'
Trend Themes
1. Topical Pain Relief Patches - Opportunities for developing non-opioid topical patches for pain relief and expanding product lines to include other therapeutic areas.
2. NSAID Topical Patches - Growing demand for NSAID patches as a safer alternative to oral pain medications, providing opportunities for pharmaceutical companies to develop and market such products.
3. Authorized and Complex Generics - Opportunities for companies to leverage existing knowledge and market authorized and complex generic medications in niche therapeutic categories.
Industry Implications
1. Pharmaceuticals - Opportunities for pharmaceutical companies to develop and market non-opioid topical patches for pain relief and expand product lines to include other therapeutic areas.
2. Medical Devices - Growing demand for topical pain relief patches results in opportunities for medical device companies to develop and manufacture such products.
3. Healthcare Technology - Opportunities for healthcare technology companies to improve delivery systems and connectivity of topical pain relief patches to enhance patient convenience and care outcomes.